Collegium Pharmaceutical (NASDAQ: COLL) nominates Michael Donovan as director as John Fallon retires

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Collegium Pharmaceutical, Inc. announced changes to its board of directors. The board approved the nomination of Michael Donovan, 60, an audit Partner at Ernst & Young LLP since 2002, to stand for election at the 2026 Annual Meeting of Shareholders.

The company also disclosed that John Fallon, M.D., a director since 2016, will not stand for re-election and will retire from the board at the Annual Meeting. His decision is described as part of ongoing board refreshment and succession planning and not due to any disagreement with the company.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Director nominee age: 60 years EY partner tenure: since 2002 Life sciences experience: over 36 years +1 more

4 metrics

Director nominee age 60 years Age of Michael Donovan at time of nomination

EY partner tenure since 2002 Michael Donovan has served as audit Partner at Ernst & Young LLP

Life sciences experience over 36 years Michael Donovan’s business, accounting and financial experience

Director service start 2016 Year John Fallon, M.D., began serving as a director

Key Terms

Annual Meeting of Shareholders, board refreshment, board succession planning, Certified Public Accountant

4 terms

Annual Meeting of Shareholders financial

"to stand for election at the Company’s 2026 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

board refreshment financial

"part of the Board’s continued focus of board refreshment and board succession planning"

Board refreshment is the deliberate replacement or addition of corporate board members to bring new skills, perspectives or energy to a company’s oversight team. For investors, it matters because a refreshed board can change a company’s strategy, improve oversight of management and reduce risk—similar to updating the coaching staff of a sports team to fix weaknesses and boost future performance, which can influence investor confidence and the stock price.

board succession planning financial

"board refreshment and board succession planning, and not the result of any disagreement"

Certified Public Accountant financial

"Mr. Donovan received a B.S. in Business Administration ... and is a Certified Public Accountant (active)."

A certified public accountant (CPA) is a licensed accounting professional who has passed rigorous exams and met education and experience requirements to prepare, review, and officially certify financial statements and tax filings. For investors, a CPA's involvement is like a neutral referee confirming that a company's reported numbers are accurate and follow accounting rules, which improves trust in financial reports and lowers the risk of unexpected errors or misleading information.

Understanding 8-K Material Events →

04/07/2026 - 04:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2, 2026

COLLEGIUM PHARMACEUTICAL, INC.

(Exact name of registrant as specified in its charter)


Virginia	001-37372	03-0416362
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

	100 Technology Center Drive
	Suite 300
	Stoughton, MA 02072
	(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 713-3699

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	COLL	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Principal Officers; Election of Directors

Director Nominee

On April 6, 2026, the board of directors (“Board”) of Collegium Pharmaceutical, Inc. (the “Company”) approved the nomination of Michael Donovan to stand for election at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”).

Mr. Donovan, 60, has served as an audit Partner at Ernst & Young LLP (“EY”) since 2002. He has held several leadership roles at EY including Office Managing Partner of EY’s biotechnology office in Kendall Square from 2014 to 2024 and East Region Biotechnology Leader. Mr. Donovan brings to our Board financial expertise obtained from his extensive business, accounting and financial background from over 36 years of experience serving public and private companies in the life sciences industry. During his tenure at EY, he has worked on hundreds of private and public company audits, private and public financings including IPOs, M&A transactions, corporate license and collaboration agreements, spin-outs and product launches. Mr. Donovan received a B.S. in Business Administration from Merrimack College and is a Certified Public Accountant (active).

Director Retirement

On April 2, 2026, John Fallon, M.D., a current member of the Board, advised the Board that he will not stand for re-election at the Annual Meeting and will retire from the Board at that time. Dr. Fallon has served as a director since 2016, and he will continue as a director until the Annual Meeting.

The Company extends its deepest gratitude to Dr. Fallon for his distinguished service to the Board and lasting contributions to the Company.

Dr. Fallon’s decision not to stand for re-election is part of the Board’s continued focus of board refreshment and board succession planning, and not the result of any disagreement with the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Collegium Pharmaceutical, Inc.

			By:			/s/ Colleen Tupper
						Colleen Tupper
						Executive Vice President and Chief Financial Officer

Dated: April 2, 2026

Source: View Original Filing on SEC EDGAR

FAQ

What board change did Collegium Pharmaceutical (COLL) announce in this 8-K?

Collegium Pharmaceutical announced that its board nominated Michael Donovan to stand for election at the 2026 Annual Meeting and that director John Fallon, M.D., will retire and not stand for re-election as part of ongoing board refreshment and succession planning.

Who is Michael Donovan, the new director nominee at Collegium Pharmaceutical (COLL)?

Michael Donovan is 60 and has been an audit Partner at Ernst & Young LLP since 2002. He has held leadership roles in EY’s biotechnology practice and brings over 36 years of financial, accounting and life sciences experience to Collegium’s board.

When will John Fallon, M.D., retire from Collegium Pharmaceutical (COLL)’s board?

John Fallon, M.D., will retire from Collegium Pharmaceutical’s board at the 2026 Annual Meeting of Shareholders. He has served as a director since 2016 and will continue in that role until the Annual Meeting, according to the company’s disclosure.

Did John Fallon, M.D., leave Collegium Pharmaceutical (COLL) due to a disagreement?

No. Collegium Pharmaceutical states that John Fallon’s decision not to stand for re-election is part of the board’s continued focus on board refreshment and succession planning, and explicitly notes it is not the result of any disagreement with the company.

What experience does Michael Donovan bring to Collegium Pharmaceutical (COLL)’s board?

Michael Donovan brings extensive experience from over 36 years serving public and private life sciences companies. At Ernst & Young, he has led biotechnology offices, overseen audits, IPOs, financings, M&A, license and collaboration agreements, spin-outs and product launches, and is a Certified Public Accountant.

Filing Exhibits & Attachments

3 documents